

# **Starr Cancer Consortium Retreat**

Cold Spring Harbor Laboratory, April 30 – May 1, 2018

**Monday, April 30, 2018**

**Note: Presenter names will be updated based on submitted abstracts. Reminder, abstracts are due March 29, 2018. Instructions can be found at [www.starrcancer.org](http://www.starrcancer.org)**

9:00 – 11:00 am	<i>Attendee Arrival and Check In</i>		<b>(Grace Auditorium Lobby)</b>
11:00 am	<i>Welcome and Opening Remarks</i> Bruce Stillman President Cold Spring Harbor Laboratory		<b>(Grace Auditorium)</b>
11:10 am – 12:30 pm	<i>Plenary Session</i>		<b>(Grace Auditorium)</b>
11:10 am	David Lyden	<i>Circulating Exosomal microRNA as Biomarkers of Medulloblastoma Progression, Metastasis, and Recurrence</i>	
11:30 am	Michael Kharas	<i>Translation Regulation in Acute Myeloid Leukemia</i>	
11:50 am	Hans-Guido Wendel	<i>Exploring the eIF4A RNA Helicase as a New Cancer Drug Target</i>	
12:10 pm	Sanford Simon	<i>Creation of Mouse Models for Fibrolamellar Hepatocellular Carcinoma</i>	
12:30 – 2:00 pm	<i>Lunch</i>		<b>(Blackford Hall)</b>
2:00 – 3:20 pm	<i>Plenary Session</i>		<b>(Grace Auditorium)</b>
2:00 pm	Marco Seandel	<i>The Paternal Germline as a Source of de novo Cancer Risk in Offspring</i>	
2:20 pm	Ethel Cesarman	<i>Elucidating the Etiologic Role of Linker Histone Mutations in Hematological Malignancy</i>	
2:40 pm	Christopher Vakoc	<i>Targeting the Chromatin Reader Protein TRIM33 as Epigenetic Therapy in B Cell Neoplasms</i>	
3:00 pm	Alexander Meissner	<i>Discovery of Epigenetic Drivers of Tumor Evolution</i>	

3:20– 4:10 pm      *First Poster Session (With Coffee Break)*      **(Grace Lobby & Patio)**

4:10 – 5:10 pm      *Plenary Session*      **(Grace Auditorium)**

4:10 pm      Samie Jaffrey      *A Massively Parallel Protein Synthesis Platform for Functional Screening of Cancer Proteomes*

4:30 pm      Ann Mullally      *Personalized Immunotherapy for the Treatment of Hematological Malignancies*

4:50 pm      Gabriel Victora      *Tracking T Cell-Antigen Presenting Cell Contacts within Tumors in vivo*

5:30 – 6:00 pm      *Wine and Cheese Reception (Posters available)*      **(Grace Patio)**

6:00 – 7:00 pm      *Banquet Dinner*      **(Mayr Dining Room, Blackford Hall)**

7:10 – 8:10 pm      *Plenary Session*      **(Grace Auditorium)**

7:10 pm      Alex Kentsis      *Epigenetic Control of DNA Transposition in Embryonal Cancers*

7:30 pm      Eliezer Van Allen      *Patient-Driven Molecular Characterization of Rare and Refractory Germ Cell Tumors*

7:50 pm      Lukas Dow      *Investigating Cancer-Associated Structural Genomic Rearrangements Using in vivo Genome Editing*

8:10 pm      Titia de Lange      *Telomere Crisis and Chromosome Shattering in Cancer*

***End of Day One***

## Tuesday, May 1, 2018

8:30 – 9:50 am	<b><i>Plenary Session</i></b>	<b>(Grace Auditorium)</b>
8:30 am	Je H. Lee	<i>Translating Molecular Profiles into Clinical Biomarkers Using Spatially Defined RNA Sequencing in situ</i>
8:50 am	Michael Yaffe	<i>Mechanism-Based Targeting of RNA Binding Protein Networks for Chemo-Sensitization in Non-Small Cell Lung Cancer (NSCLC)</i>
9:10 am	Robert Darnell	<i>Identifying RNA-Binding Proteins as a Novel Class of Therapeutic Targets in Glioblastoma Cancer Stem-Like Cells</i>
9:30 am	Charles Sawyers	<i>Transcriptional Reprogramming Drives Cancer Cell Heterogeneity and Drug Resistance</i>
9:50 – 10:40 am	<b><i>Second Poster Session (With Coffee Break)</i></b>	<b>(Grace Lobby &amp; Patio)</b>
10:40 – 12:00 noon	<b><i>Plenary Session</i></b>	<b>(Grace Auditorium)</b>
10:40 am	Omar Abdel-Wahab	<i>Dissecting Micro-Environmental Contributions to the Pathogenesis of Myelodysplastic Syndromes</i>
11:00 am	Richard White	<i>An in vivo CRISPR Screen for Melanoma Progression in Zebrafish</i>
11:20 am	Kivanc Birsoy	<i>Dissecting SHMT2 Function as a Metabolic Driver of Lymphomagenesis</i>
11:50 am	<b><i>Closing Remarks</i></b> Executive Committee	
12:00 pm – 1:00 pm	<b><i>Attendee Departure - Lunch Available</i></b>	

## Poster Presentations

Posters will be displayed for the duration of the Retreat. Posters will be presented in two poster sessions. Each poster's presenter will be available at his/her poster during the assigned session. Session assignments are listed in the right-hand column.

Session 1: Monday, April 30<sup>th</sup>; 3:20 – 4:10 pm

Session 2: Tuesday, May 1<sup>st</sup>; 9:50 – 10:40 am

		<b>Session</b>
John Blenis	<i>Biochemical and genetic investigation of oncogenic TOR-dependent regulation of RNA metabolism and tumorigenesis using cross-species approaches</i>	<b>1</b>
Michael Kharas	<i>The mRNA methylation program in leukemia</i>	<b>2</b>
Ross Levine	<i>Clonal Hematopoiesis as a Driver of Adverse Clinical Outcome</i>	<b>1</b>
Ari Melnick	<i>Defining the cellular origin and mechanistic basis for therapy resistant B-cell lymphomas</i>	<b>2</b>
Elaine Fuchs	<i>Dissecting the Metabolic Regulation of Tumor Initiating Stem Cells</i>	<b>1</b>
Rona Yaeger	<i>Defining Key Genomic Alterations in the Carcinogenesis of Colitis-Associated Cancers</i>	<b>2</b>
Lisa Giulino Roth	<i>Modulation of viral latency in EBV-associated lymphomas as a mechanism to sensitize tumors to EBV-directed cellular therapy</i>	<b>1</b>
Sanford Simon	<i>High Throughput Identification of Apoptosis Sensitizing Compounds in Fibrolamellar Hepatocellular Carcinoma</i>	<b>2</b>
Marcin Imielinski	<i>Deciphering signatures of broken DNA repair pathways in long-range cancer whole genome sequences</i>	<b>1</b>

Lloyd Trotman	<i>Validation of a New Mouse Model System for Castration Resistant Metastatic Prostate Cancer</i>	<b>2</b>
Christopher Mason	<i>Single-Cell Resolution of Emergent Clones in the Myelodysplastic Syndromes (MDS) During Therapy and Disease Progression</i>	<b>1</b>
Jonathan Rosenberg	<i>ERCC2 somatic mutations as biomarkers of platinum chemotherapy sensitivity in urothelial carcinoma and other platinum-treated tumors</i>	<b>2</b>
Omar Abdel-Wahab	<i>Understanding and Targeting Spliceosomal-Mutation Hematopoietic Malignancies</i>	<b>1</b>
Omar Abdel-Wahab	<i>Understanding and Targeting Spliceosomal-Mutation Hematopoietic Malignancies</i>	<b>2</b>
Roberta Zappasodi	<i>Identification of Tumor Cell and Microenvironmental Determinants of Response to Immune Checkpoint Blockade in Lung Cancer</i>	<b>1</b>